Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Chubb
Federal Trade Commission
Covington
Boehringer Ingelheim
QuintilesIMS

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,413,980

« Back to Dashboard

Which drugs does patent 6,413,980 protect, and when does it expire?

Patent 6,413,980 protects ELIQUIS and is included in one NDA.

This patent has twenty-eight patent family members in twenty-four countries.

Summary for Patent: 6,413,980
Title: Nitrogen containing heterobicycles as factor Xa inhibitors
Abstract:The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
Inventor(s): Fevig; John M. (Lincoln University, PA), Cacciola; Joseph (Newark, DE), Clark; Charles G. (Cherry Hill, NJ), Han; Qi (Wilmington, DE), Lam; Patrick Yuk Sun (Chadds Ford, PA), Pinto; Donald J.P. (Kennett Square, PA), Pruitt; James R. (Landenberg, PA), Quan; Mimi L. (Newark, DE), Rossi; Karen A. (Newark, DE)
Assignee: Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Application Number:09/470,326
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,413,980
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,413,980

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT) ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PULMONARY EMBOLISM (PE) ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-001 Dec 28, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y Y REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-002 Dec 28, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM ➤ Sign Up
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-002 Dec 28, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Moodys
Argus Health
Merck
Cantor Fitzgerald
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.